Vaginal Progesterone for Threatened Abortion
Vaginal progesterone is NOT routinely recommended for threatened abortion (vaginal bleeding with closed cervix in early pregnancy), as the highest quality evidence shows no significant benefit in improving live birth rates in the general population with this condition.
Evidence Summary
The most definitive evidence comes from the PRISM trial 1, a large multicenter, double-blind, placebo-controlled RCT of 4,153 women with early pregnancy bleeding. This study found that 400 mg vaginal progesterone twice daily from presentation through 16 weeks of gestation did not significantly increase live births ≥34 weeks compared to placebo (75% vs 72%; relative rate 1.03,95% CI 1.00-1.07; P=0.08).
A subsequent Australian trial 2 confirmed these findings, showing no benefit in live birth rates with 400 mg vaginal progesterone nightly (82.4% vs 84.2%; P=0.683).
Critical Distinction: Threatened Abortion vs. Short Cervix
It is essential to understand that threatened abortion (vaginal bleeding) is NOT the same as asymptomatic short cervix. The guidelines you may be familiar with regarding vaginal progesterone apply specifically to:
- Asymptomatic women with short cervix (≤20 mm) on transvaginal ultrasound 3
- Women with prior spontaneous preterm birth 4, 5
These are different clinical scenarios than threatened abortion and should not be conflated.
Important Subgroup Exception
The PRISM trial identified one significant subgroup where progesterone may be beneficial: women with current bleeding AND a history of three or more previous miscarriages showed improved live birth rates with progesterone (72% vs 57%; relative rate 1.28,95% CI 1.08-1.51; P=0.004) 1, 6.
Recommended Approach by History:
- No previous miscarriages: Do not prescribe progesterone (no benefit demonstrated)
- One or two previous miscarriages: Progesterone may be considered based on shared decision-making, though evidence is marginal 1, 6
- Three or more previous miscarriages: Prescribe vaginal progesterone (NNT=8) 7, 6
Dosing Regimen (If Indicated)
When progesterone is prescribed for the subgroup with recurrent losses:
- Vaginal micronized progesterone 400 mg twice daily (most studied regimen) 1, 2
- Alternative: Oral dydrogesterone may be considered based on recent network meta-analysis 8
- Start: At presentation with bleeding
- Continue: Through 12-16 weeks of gestation
- Contraindications: Severe peanut allergy (micronized capsules contain peanut oil; use gel formulation instead), hormone receptor-positive breast cancer 3
Common Pitfalls to Avoid
Do not confuse threatened abortion with preterm labor or short cervix management - these are entirely different indications with different evidence bases 4
Do not prescribe progesterone for symptomatic preterm labor - guidelines explicitly state there is no evidence of effectiveness 4
Do not use 17-OHPC (intramuscular progesterone) for threatened abortion - this formulation is specifically for women with prior spontaneous preterm birth, not for threatened miscarriage 5
Avoid prescribing progesterone routinely without assessing miscarriage history - the overall population does not benefit 1, 2
Safety Profile
Progesterone has not been associated with increased adverse events, congenital abnormalities, or long-term harm to offspring in multiple studies 1, 2, 6. However, the lack of efficacy in most women with threatened abortion means routine use cannot be justified.